This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Study Evaluating Prevenar in the Prevention of Invasive Pneumococcal Disease (IPD) in the Paediatric Population in Spain.

This study has been completed.
Information provided by (Responsible Party):
Pfizer Identifier:
First received: September 13, 2005
Last updated: November 28, 2012
Last verified: November 2012
The aim of this study is to evaluate the postlicensure effectiveness of Prevnar in the prevention of IPD in the Spanish paediatric population (children younger than 5 years)

Condition Intervention
Invasive Pneumococcal Disease Drug: Pneumococcal 7-valent conjugate vaccine Prevnar

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Effectiveness of Prevnar in the Prevention on IPD in the Paediatric Population in Spain

Resource links provided by NLM:

Further study details as provided by Pfizer:

Biospecimen Retention:   Samples Without DNA
Samples without DNA

Enrollment: 408
Study Start Date: May 2003
Study Completion Date: December 2005
Primary Completion Date: December 2005 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Children from 0-5 years of age evaluated for IPD
Drug: Pneumococcal 7-valent conjugate vaccine Prevnar
Other Name: PREVNAR


Ages Eligible for Study:   up to 5 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
All public and private hospitals with a pediatric department belonging to one of the two autonomous communities.

Inclusion Criteria:

  • All children from 0 up to 5 years attending to the hospital's emergency department will be evaluated for IPD.
  • Diagnosis of IPD will be based on positive pneumococcal isolation in any sterile location, such us blood or spinal fluid.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00227188

Pfizer Investigational Site
Bilbao, Spain, 48903
Sponsors and Collaborators
Study Director: Pfizer Call Center Pfizer
  More Information

Additional Information:
Responsible Party: Pfizer Identifier: NCT00227188     History of Changes
Other Study ID Numbers: 0887-101317
Study First Received: September 13, 2005
Last Updated: November 28, 2012

Additional relevant MeSH terms:
Pneumococcal Infections
Streptococcal Infections
Gram-Positive Bacterial Infections
Bacterial Infections
Heptavalent Pneumococcal Conjugate Vaccine
Immunologic Factors
Physiological Effects of Drugs processed this record on August 23, 2017